BRPI0516718A - forma de dosagem de ibuprofeno de liberação modificada - Google Patents
forma de dosagem de ibuprofeno de liberação modificadaInfo
- Publication number
- BRPI0516718A BRPI0516718A BRPI0516718-3A BRPI0516718A BRPI0516718A BR PI0516718 A BRPI0516718 A BR PI0516718A BR PI0516718 A BRPI0516718 A BR PI0516718A BR PI0516718 A BRPI0516718 A BR PI0516718A
- Authority
- BR
- Brazil
- Prior art keywords
- ibuprofen
- dosage form
- modified release
- administration
- hours following
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
FORMA DE DOSAGEM DE IBUPROFENO DE LIBERAçãO MODIFICADA. A presente invenção refere-se a uma forma de dosagem sólida para administração oral de ibuprofeno compreendendo uma formulação de liberação modificada de ibuprofeno que provê um efeito de explosão imediato e em seguida uma liberação sustentada de ibuprofeno suficiente para manter níveis sanguíneos de pelo menos 6,4 <109>g/ml durante um período prolongado de pelo menos 8 horas seguindo administração em uma dose única. A forma de dosagem libera ibuprofeno em uma taxa suficiente para inicialmente aplicar uma quantidade eficaz de ibuprofeno dentro de cerca de 2,0 horas seguindo administração. A forma de dosagem então subseqüentemente aplica a quantidade restante de ibuprofeno em uma taxa relativamente constante suficiente para manter um nível de ibuprofeno durante um período de aplicação predeterminado por pelo menos 8 horas.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61493204P | 2004-09-30 | 2004-09-30 | |
US60/614,932 | 2004-09-30 | ||
US68963105P | 2005-06-10 | 2005-06-10 | |
US60/689,631 | 2005-06-10 | ||
US11/238,802 | 2005-09-29 | ||
US11/238,802 US20060068009A1 (en) | 2004-09-30 | 2005-09-29 | Modified release ibuprofen dosage form |
PCT/US2005/035630 WO2006039692A2 (en) | 2004-09-30 | 2005-09-30 | Modified release ibuprofen dosage form |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0516718A true BRPI0516718A (pt) | 2008-09-16 |
BRPI0516718B1 BRPI0516718B1 (pt) | 2019-05-14 |
BRPI0516718B8 BRPI0516718B8 (pt) | 2021-05-25 |
Family
ID=36099442
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0516718A BRPI0516718B8 (pt) | 2004-09-30 | 2005-09-30 | formulação de liberação modificada de ibuprofeno fornecendo liberação imediata e prolongada do fármaco |
Country Status (13)
Country | Link |
---|---|
US (1) | US20060068009A1 (pt) |
EP (1) | EP1793809B1 (pt) |
JP (1) | JP2008515802A (pt) |
KR (1) | KR20070064352A (pt) |
AU (1) | AU2005292185B2 (pt) |
BR (1) | BRPI0516718B8 (pt) |
CA (1) | CA2582150C (pt) |
HK (1) | HK1107002A1 (pt) |
IL (1) | IL182144A (pt) |
MX (1) | MX2007003919A (pt) |
NZ (1) | NZ554213A (pt) |
PL (1) | PL1793809T3 (pt) |
WO (1) | WO2006039692A2 (pt) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
DE102004032049A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
US20070077297A1 (en) | 2004-09-30 | 2007-04-05 | Scolr Pharma, Inc. | Modified release ibuprofen dosage form |
DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
US7749537B2 (en) * | 2006-12-04 | 2010-07-06 | Scolr Pharma, Inc. | Method of forming a tablet |
DE102007011485A1 (de) | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Darreichungsform mit erschwertem Missbrauch |
BRPI0906467C1 (pt) | 2008-01-25 | 2021-05-25 | Gruenenthal Gmbh | forma de dosagem farmacêutica com formato exterior modificado resistente à ruptura e com liberação controlada |
LT2273983T (lt) | 2008-05-09 | 2016-10-25 | Grünenthal GmbH | Tarpinės miltelių kompozicijos gamybos būdas ir galutinė kieta dozavimo forma naudojant purškalo kietinimo stadija |
US20130115250A1 (en) * | 2009-05-13 | 2013-05-09 | Wyeth Llc | Burst Drug Release Compositions |
TWI478733B (zh) * | 2009-05-13 | 2015-04-01 | Wyeth Llc | 突釋藥物釋放組合物 |
KR101747156B1 (ko) | 2009-07-22 | 2017-06-27 | 그뤼넨탈 게엠베하 | 산화-안정화된 탬퍼-내성 용량형 |
TW201105316A (en) | 2009-07-22 | 2011-02-16 | Gruenenthal Gmbh | Hot-melt extruded pharmaceutical dosage form |
RU2607499C2 (ru) | 2010-09-02 | 2017-01-10 | Грюненталь Гмбх | Устойчивая к разрушению лекарственная форма, которая содержит анионный полимер |
MX2013002377A (es) | 2010-09-02 | 2013-04-29 | Gruenenthal Gmbh | Forma de dosificacion resistente a manipulacion que comprende una sal inorganica. |
EA201400172A1 (ru) | 2011-07-29 | 2014-06-30 | Грюненталь Гмбх | Устойчивая к разрушению таблетка, которая обеспечивает немедленное высвобождение лекарственного средства |
EA201400173A1 (ru) | 2011-07-29 | 2014-06-30 | Грюненталь Гмбх | Устойчивая к разрушению таблетка, которая обеспечивает немедленное высвобождение лекарственного средства |
JP6117249B2 (ja) | 2012-02-28 | 2017-04-19 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 薬理学的に活性な化合物および陰イオン性ポリマーを含むタンパーレジスタント剤形 |
JP6282261B2 (ja) | 2012-04-18 | 2018-02-21 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 不正使用防止および過量放出防止医薬剤形 |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
AR096439A1 (es) | 2013-05-29 | 2015-12-30 | Gruenenthal Gmbh | Forma de dosificación resistente al uso indebido que contiene una o más partículas |
AU2014273227B2 (en) | 2013-05-29 | 2019-08-15 | Grunenthal Gmbh | Tamper-resistant dosage form containing one or more particles |
CA2917136C (en) | 2013-07-12 | 2022-05-31 | Grunenthal Gmbh | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
WO2015016256A1 (ja) * | 2013-07-30 | 2015-02-05 | ライオン株式会社 | 錠剤 |
JP6480936B2 (ja) | 2013-11-26 | 2019-03-13 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | クライオミリングによる粉末状医薬組成物の調製 |
JP6443891B2 (ja) * | 2014-01-31 | 2018-12-26 | 塩野義製薬株式会社 | 徐放性製剤 |
AU2015261060A1 (en) | 2014-05-12 | 2016-11-03 | Grunenthal Gmbh | Tamper resistant immediate release capsule formulation comprising Tapentadol |
EA201692388A1 (ru) | 2014-05-26 | 2017-05-31 | Грюненталь Гмбх | Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы |
MX2017013637A (es) | 2015-04-24 | 2018-03-08 | Gruenenthal Gmbh | Forma de dosificacion resistente a alteraciones con liberacion inmediata y resistencia contra la extraccion por solventes. |
CA2998259A1 (en) | 2015-09-10 | 2017-03-16 | Grunenthal Gmbh | Protecting oral overdose with abuse deterrent immediate release formulations |
CN112168796B (zh) * | 2020-09-28 | 2022-10-25 | 北京诺康达医药科技股份有限公司 | 双相缓释系统控制释放的药物缓释制剂及其制备方法 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2055685T3 (es) * | 1986-11-14 | 1994-09-01 | Puetter Medice Chem Pharm | Procedimiento para la obtencion de un medicamento que contiene ibuprofen. |
US4786503A (en) * | 1987-04-06 | 1988-11-22 | Alza Corporation | Dosage form comprising parallel lamine |
US4814181A (en) * | 1987-09-03 | 1989-03-21 | Alza Corporation | Dosage form comprising fast agent delivery followed by slow agent delivery |
US4990535A (en) * | 1989-05-03 | 1991-02-05 | Schering Corporation | Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine |
US5009895A (en) * | 1990-02-02 | 1991-04-23 | Merck & Co., Inc. | Sustained release with high and low viscosity HPMC |
GB9603699D0 (en) * | 1996-02-21 | 1996-04-17 | Boots Co Plc | Therapeutic composition |
US6361794B1 (en) * | 1996-06-12 | 2002-03-26 | Basf Corporation | Method of making ibuprofen and narcotic analgesic composition |
GB9702392D0 (en) * | 1997-02-06 | 1997-03-26 | Boots Co Plc | Therapeutic agents |
AU8699298A (en) * | 1997-08-11 | 1999-03-01 | Alza Corporation | Prolonged release active agent dosage form adapted for gastric retention |
IT1301966B1 (it) * | 1998-07-30 | 2000-07-20 | Zambon Spa | Composizioni farmaceutiche ad attivita' analgesica |
GB9816899D0 (en) * | 1998-08-05 | 1998-09-30 | Boots Co Plc | Therapeutic agents |
US5997905A (en) * | 1998-09-04 | 1999-12-07 | Mcneil-Ppc | Preparation of pharmaceutically active particles |
DE10001166A1 (de) * | 2000-01-13 | 2001-07-19 | Merckle Gmbh | Anellierte Pyrrolverbindungen, diese enthaltende pharmazeutische Mittel und deren Verwendung |
DE10003757A1 (de) * | 2000-01-28 | 2001-08-02 | Knoll Ag | Ibuprofen-Wirkstoffzubereitung |
US6673369B2 (en) * | 2001-08-29 | 2004-01-06 | Ranbaxy Laboratories Limited | Controlled release formulation |
US6592901B2 (en) * | 2001-10-15 | 2003-07-15 | Hercules Incorporated | Highly compressible ethylcellulose for tableting |
US20040047904A1 (en) * | 2001-11-13 | 2004-03-11 | Motohiro Ohta | Amino acid-containing tablets quickly disintegrating in the oral cavity and process for producing the same |
US20040122048A1 (en) * | 2002-10-11 | 2004-06-24 | Wyeth Holdings Corporation | Stabilized pharmaceutical composition containing basic excipients |
US20040121010A1 (en) * | 2002-10-25 | 2004-06-24 | Collegium Pharmaceutical, Inc. | Pulsatile release compositions of milnacipran |
JP2006515861A (ja) * | 2002-11-29 | 2006-06-08 | フォレスト ラボラトリーズ インコーポレーテッド | イブプロフェンとオキシコドンを含有する単位剤形での急性痛の治療方法 |
US20070077297A1 (en) * | 2004-09-30 | 2007-04-05 | Scolr Pharma, Inc. | Modified release ibuprofen dosage form |
-
2005
- 2005-09-29 US US11/238,802 patent/US20060068009A1/en not_active Abandoned
- 2005-09-30 WO PCT/US2005/035630 patent/WO2006039692A2/en active Application Filing
- 2005-09-30 BR BRPI0516718A patent/BRPI0516718B8/pt active IP Right Grant
- 2005-09-30 NZ NZ554213A patent/NZ554213A/en not_active IP Right Cessation
- 2005-09-30 PL PL05805851T patent/PL1793809T3/pl unknown
- 2005-09-30 MX MX2007003919A patent/MX2007003919A/es active IP Right Grant
- 2005-09-30 CA CA2582150A patent/CA2582150C/en active Active
- 2005-09-30 JP JP2007534883A patent/JP2008515802A/ja active Pending
- 2005-09-30 EP EP05805851A patent/EP1793809B1/en active Active
- 2005-09-30 KR KR1020077009626A patent/KR20070064352A/ko active IP Right Grant
- 2005-09-30 AU AU2005292185A patent/AU2005292185B2/en active Active
-
2007
- 2007-03-22 IL IL182144A patent/IL182144A/en not_active IP Right Cessation
- 2007-11-15 HK HK07112497.6A patent/HK1107002A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP1793809A4 (en) | 2010-05-12 |
BRPI0516718B8 (pt) | 2021-05-25 |
HK1107002A1 (en) | 2008-03-28 |
KR20070064352A (ko) | 2007-06-20 |
AU2005292185A1 (en) | 2006-04-13 |
IL182144A0 (en) | 2007-07-24 |
WO2006039692A2 (en) | 2006-04-13 |
WO2006039692A3 (en) | 2006-06-15 |
EP1793809A2 (en) | 2007-06-13 |
CA2582150C (en) | 2014-01-14 |
MX2007003919A (es) | 2007-09-07 |
US20060068009A1 (en) | 2006-03-30 |
CA2582150A1 (en) | 2006-04-13 |
BRPI0516718B1 (pt) | 2019-05-14 |
NZ554213A (en) | 2010-01-29 |
PL1793809T3 (pl) | 2012-12-31 |
EP1793809B1 (en) | 2012-07-11 |
AU2005292185B2 (en) | 2010-06-17 |
JP2008515802A (ja) | 2008-05-15 |
IL182144A (en) | 2014-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0516718A (pt) | forma de dosagem de ibuprofeno de liberação modificada | |
WO2008069941A3 (en) | Modified release ibuprofen solid oral dosage form | |
EA201100304A1 (ru) | Система доставки лекарственного средства, содержащего прогестин | |
GEP20125628B (en) | Pharmaceutical compositions containing antagonist anti-cd40 antibody | |
BRPI0516830A (pt) | composições de droga de liberação sustentada convenientemente implantáveis | |
ATE543491T1 (de) | Kombinationspräparat enthaltend ibuprofen und paracetamol | |
WO2007103200A3 (en) | Oral controlled release formulation for sedative and hypnotic agents | |
BR0309620A (pt) | Métodos e formas de dosagem para liberação controlada de oxicodona | |
EA200700049A1 (ru) | Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением | |
EA201190127A1 (ru) | Фармацевтические составы нитазоксанида с контролируемым высвобождением | |
ATE493973T1 (de) | Irbesartan enthaltende pharmazeutische zusammensetzung | |
ATE302616T1 (de) | Oral anzuwendende arzneizusammensetzungen mit gesteuerter wirkstoffabgabe | |
BRPI0414565A (pt) | composições farmacêuticas e métodos que compreendem combinações de derivados de 2-alquilideno-19-nor-vitamina d e um bisfosfonato | |
RS52867B (en) | GLATIRAMER ACETATOM AND RAZAGILIN COMBINED THERAPY FOR MULTIPLE SCLEROSIS | |
CO5640120A2 (es) | Formulacion y metodods para el tratamiento de trombocitemia | |
BR0215148A (pt) | Composições farmacêuticas de agonista parcial 5ht4 | |
EA200701923A1 (ru) | Лекарственная форма для перорального введения витамина | |
AR070025A1 (es) | Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica | |
FR2878161B1 (fr) | Forme medicamenteuse orale, solide et concue pour eviter le mesusage | |
NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
IL196425A0 (en) | Pharmaceutical compositions containing ibuprofen and famotidine | |
MX2009011900A (es) | Curacion de herida diabetica. | |
BR112013010829B8 (pt) | Composição farmacêutica intravenosa para proporcionar alívio da dor e/ou da inflamação | |
AR053928A1 (es) | Metodos reactivos para el tratamiento de trastornos inflamatorios | |
Kirschneck et al. | Effects of the highly COX-2-selective analgesic NSAID etoricoxib on the rate of orthodontic tooth movement and cranial growth |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A ANUIDADE. |
|
B08G | Application fees: restoration [chapter 8.7 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B07C | Technical examination (opinion): republication [chapter 7.3 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B09X | Republication of the decision to grant [chapter 9.1.3 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 14/05/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 14/05/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/09/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |